Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer.

about

Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer.

Item

http://www.wikidata.org/entity/Q47161687

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Updates on the Management of A ...... Differentiated Thyroid Cancer.

@en

Updates on the Management of A ...... Differentiated Thyroid Cancer.

@nl

type

Item

label

Updates on the Management of A ...... Differentiated Thyroid Cancer.

@en

Updates on the Management of A ...... Differentiated Thyroid Cancer.

@nl

prefLabel

Updates on the Management of A ...... Differentiated Thyroid Cancer.

@en

Updates on the Management of A ...... Differentiated Thyroid Cancer.

@nl

P1476

Updates on the Management of A ...... Differentiated Thyroid Cancer.

@en

P2093

Francesco Frasca

http://www.w3.org/2001/XMLSchema#string

Kate Newbold

http://www.w3.org/2001/XMLSchema#string

P2860

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer

Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies.

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

Timing of multikinase inhibitor initiation in differentiated thyroid cancer.

Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.

Motesanib diphosphate in progressive differentiated thyroid cancer.

BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer

P304

312

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.3389/FENDO.2017.00312

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Dario Tumino

P577

2017-11-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29209273

http://www.w3.org/2001/XMLSchema#string

P932

5702018

http://www.w3.org/2001/XMLSchema#string